S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NYSE:CRLCharles River Laboratories Intl. Stock Price, Forecast & News

$219.65
+9.41 (+4.48 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$211.22
Now: $219.65
$220.54
50-Day Range
$169.00
MA: $191.54
$221.60
52-Week Range
$95.58
Now: $219.65
$221.97
Volume340,800 shs
Average Volume423,751 shs
Market Capitalization$10.91 billion
P/E Ratio40.45
Dividend YieldN/A
Beta1.22
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves biopharmaceutical companies; biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic, and consumer product companies; contract research and contract manufacturing organizations; other commercial entities; and hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More
Charles River Laboratories Intl. logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.62 billion
Cash Flow$10.78 per share
Book Value$33.45 per share

Profitability

Net Income$252.02 million

Miscellaneous

Employees17,100
Market Cap$10.91 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$219.65
+9.41 (+4.48 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

How has Charles River Laboratories Intl.'s stock price been impacted by Coronavirus (COVID-19)?

Charles River Laboratories Intl.'s stock was trading at $136.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRL shares have increased by 60.8% and is now trading at $219.65.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Charles River Laboratories Intl.?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 3 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Charles River Laboratories Intl.
.

When is Charles River Laboratories Intl.'s next earnings date?

Charles River Laboratories Intl. is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Charles River Laboratories Intl.
.

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) issued its earnings results on Wednesday, August, 5th. The medical research company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.31. The medical research company had revenue of $682.60 million for the quarter, compared to the consensus estimate of $638.70 million. Charles River Laboratories Intl. had a return on equity of 21.58% and a net margin of 9.87%. The business's revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.63 earnings per share.
View Charles River Laboratories Intl.'s earnings history
.

What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?

Charles River Laboratories Intl. issued an update on its FY20 earnings guidance on Wednesday, August, 5th. The company provided earnings per share guidance of $7.05-7.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.91. The company issued revenue guidance of +7.5% to 9.0% to $2.82-2.86 billion, compared to the consensus revenue estimate of $2.77 billion.

What price target have analysts set for CRL?

18 equities research analysts have issued 1 year price targets for Charles River Laboratories Intl.'s shares. Their forecasts range from $139.00 to $255.00. On average, they expect Charles River Laboratories Intl.'s share price to reach $186.33 in the next twelve months. This suggests that the stock has a possible downside of 15.2%.
View analysts' price targets for Charles River Laboratories Intl.
.

Has Charles River Laboratories Intl. been receiving favorable news coverage?

Headlines about CRL stock have been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Charles River Laboratories Intl. earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Charles River Laboratories Intl.
.

Are investors shorting Charles River Laboratories Intl.?

Charles River Laboratories Intl. saw a drop in short interest in June. As of June 30th, there was short interest totaling 1,030,000 shares, a drop of 17.6% from the June 15th total of 1,250,000 shares. Based on an average daily trading volume, of 384,500 shares, the days-to-cover ratio is presently 2.7 days. Currently, 2.1% of the company's stock are short sold.
View Charles River Laboratories Intl.'s Short Interest
.

Who are some of Charles River Laboratories Intl.'s key competitors?

What other stocks do shareholders of Charles River Laboratories Intl. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories Intl. investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), AbbVie (ABBV), Boeing (BA), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Pfizer (PFE), Paypal (PYPL) and Intel (INTC).

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the following people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 68)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 53)
  • Mr. David P. Johst, Corp. Exec. VP, HR, Gen. Counsel & Chief Admin. Officer (Age 57)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 58)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 42)

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories Intl.'s major shareholders?

Charles River Laboratories Intl.'s stock is owned by many different institutional and retail investors. Top institutional shareholders include Copper Rock Capital Partners LLC (8.70%), FMR LLC (3.92%), FIL Ltd (1.65%), Epoch Investment Partners Inc. (1.49%), TimesSquare Capital Management LLC (1.30%) and Congress Asset Management Co. MA (1.27%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, David P Johst, David Ross Smith, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Robert J Bertolini, Stephen D Chubb and William D Barbo.
View institutional ownership trends for Charles River Laboratories Intl.
.

Which institutional investors are selling Charles River Laboratories Intl. stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Goldman Sachs Group Inc., TimesSquare Capital Management LLC, Epoch Investment Partners Inc., New York State Common Retirement Fund, Boston Trust Walden Corp, Mackay Shields LLC, and Monarch Partners Asset Management LLC. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Robert J Bertolini, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories Intl.
.

Which institutional investors are buying Charles River Laboratories Intl. stock?

CRL stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, FMR LLC, Marshall Wace LLP, CIBC Private Wealth Group LLC, Mountain Pacific Investment Advisers Inc. ID, Victory Capital Management Inc., Confluence Investment Management LLC, and Nordea Investment Management AB.
View insider buying and selling activity for Charles River Laboratories Intl.
.

How do I buy shares of Charles River Laboratories Intl.?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of CRL stock can currently be purchased for approximately $219.65.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $10.91 billion and generates $2.62 billion in revenue each year. The medical research company earns $252.02 million in net income (profit) each year or $6.73 on an earnings per share basis. Charles River Laboratories Intl. employs 17,100 workers across the globe.

What is Charles River Laboratories Intl.'s official website?

The official website for Charles River Laboratories Intl. is www.criver.com.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.